Akshay Pharma Remedies (India) Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 17-07-2024
- Paid Up Capital ₹ 2.40 M
as on 17-07-2024
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 7.77%
(FY 2023)
- Profit 99.56%
(FY 2023)
- Ebitda 78.68%
(FY 2023)
- Net Worth -0.98%
(FY 2023)
- Total Assets 12.47%
(FY 2023)
About Akshay Pharma Remedies (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.40 M, as per Ministry of Corporate Affairs (MCA) records.
Mugdha Joshi, Manoj Joshi, and Arjun Joshi serve as directors at the Company.
- CIN/LLPIN
U74900MH2011PTC214763
- Company No.
214763
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Akshay Pharma Remedies (India) Private Limited offer?
Akshay Pharma Remedies (India) Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets.
Who are the key members and board of directors at Akshay Pharma Remedies (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mugdha Joshi  | Director | 14-Mar-2011 | Current |
| Manoj Joshi | Director | 14-Mar-2011 | Current |
| Arjun Joshi | Director | 23-Mar-2022 | Current |
Financial Performance and Corporate Structure Insights of Akshay Pharma Remedies (India).
Akshay Pharma Remedies (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.77% increase. The company also saw a substantial improvement in profitability, with a 99.56% increase in profit. The company's net worth dipped by a decrease of 0.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Akshay Pharma Remedies (India)?
In 2023, Akshay Pharma Remedies (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dr. Greenz Life Sciences Private Limited
Active 20 years 13 daysMugdha Joshi and Manoj Joshi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Akshay Pharma Remedies (India)?
Unlock and access historical data on people associated with Akshay Pharma Remedies (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akshay Pharma Remedies (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akshay Pharma Remedies (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
